Extended survival times and inhibited growth of patient-derived glioblastoma brain tumours have been achieved in mice with CRISPR-Cas9 mediated...

Most pharmaceuticals don't reach the brain, leaving cognitive impairments due to diseases like mucopolysaccharidoses (MPS) hard to treat. Now, a...

This week's update includes news about two gene-edited therapies for cancer. Allogene Therapeutics' ALLO-316 has been granted Fast Track Designation...

Folding DNA into compact structures allows for efficient integration of large genes, and this might lead to new therapies for genetic diseases with...

Intellia Therapeutics recently announced that the first patient had been dosed in its Phase 1/2a CRISPR trial for acute myleoid leukaemia (AML). The...

Some of the best links we picked up around the internet

This week’s CRISPR trial update brings you the latest developments from ongoing CRISPR clinical trials, including expansion of Intellia Therapeutics’...

Last week, Intellia Therapeutics announced that it had received clearance to begin a clinical trial for NTLA-2002, an in vivo CRISPR therapy candidate...